What You Need to Know: Ligand, AVEO, and Pfizer

In this video, Motley Fool health care analyst David Williamson takes us through some of the biggest investing stories in the health care space yesterday. He tells us about Ligand's (NAS: LGND) big FDA win -- and why its relevance may be very short-lived -- and how AVEO Pharmaceuticals (NAS: AVEO) is bouncing back after taking a big hit last week and what's ahead for the company. He also discusses how pharmaceutical giant Pfizer (NYS: PFE) doesn't always get what it wants.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

The article What You Need to Know: Ligand, AVEO, and Pfizer originally appeared on Fool.com.

David Williamson owns shares of Pfizer. Max Macaluso has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.